As of 2025-07-01, the Relative Valuation of Oramed Pharmaceuticals Inc (ORMP) is (12.98) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.25 USD, the upside of Oramed Pharmaceuticals Inc based on Relative Valuation is -676.8%.
The range of the Relative Valuation is (12.86) - (12.37) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 17.2x - 17.9x | 17.4x |
| Forward P/E multiples | 18.6x - 22.0x | 20.1x |
| Fair Price | (12.86) - (12.37) | (12.98) |
| Upside | -671.4% - -649.9% | -676.8% |
| Date | P/E |
| 2025-06-27 | -3.11 |
| 2025-06-26 | -3.14 |
| 2025-06-25 | -3.15 |
| 2025-06-24 | -3.14 |
| 2025-06-23 | -3.05 |
| 2025-06-20 | -3.08 |
| 2025-06-18 | -3.11 |
| 2025-06-17 | -3.12 |
| 2025-06-16 | -3.12 |
| 2025-06-13 | -3.07 |
| 2025-06-12 | -3.24 |
| 2025-06-11 | -3.23 |
| 2025-06-10 | -3.23 |
| 2025-06-09 | -3.23 |
| 2025-06-06 | -3.21 |
| 2025-06-05 | -3.11 |
| 2025-06-04 | -3.30 |
| 2025-06-03 | -3.27 |
| 2025-06-02 | -3.44 |
| 2025-05-30 | -3.39 |
| 2025-05-29 | -3.23 |
| 2025-05-28 | -3.12 |
| 2025-05-27 | -3.10 |
| 2025-05-23 | -3.07 |
| 2025-05-22 | -3.11 |
| 2025-05-21 | -3.05 |
| 2025-05-20 | -3.11 |
| 2025-05-19 | -3.10 |
| 2025-05-16 | -3.11 |
| 2025-05-15 | -3.18 |
| 2025-05-14 | -3.20 |
| 2025-05-13 | -3.24 |
| 2025-05-12 | -3.24 |
| 2025-05-09 | -3.25 |
| 2025-05-08 | -3.31 |
| 2025-05-07 | -3.21 |
| 2025-05-06 | -3.23 |
| 2025-05-05 | -3.34 |
| 2025-05-02 | -3.36 |
| 2025-05-01 | -3.28 |
| 2025-04-30 | -3.36 |
| 2025-04-29 | -3.37 |
| 2025-04-28 | -3.24 |
| 2025-04-25 | -3.37 |
| 2025-04-24 | -3.33 |
| 2025-04-23 | -3.34 |
| 2025-04-22 | -3.31 |
| 2025-04-21 | -3.25 |
| 2025-04-17 | -3.11 |
| 2025-04-16 | -3.18 |